

**Treatment of Rheumatoid Arthritis with Certolizumab
Pegol: Results from PROACTIVE, a Non-Interventional
Study in the UK and Ireland**

Supplementary Data

Supplementary Table 1. Healthcare resource utilization over 78 weeks

Mean (SD)	Week 12 Responders (n=80)	Week 12 Non-Responders (n=31)
Number of hospitalizations	1.00 (0.00)	1.00 (0.00)
Length of hospitalization stay (days)	3.13 (3.27)	2.33 (1.53)
Number of emergency room visits	1.00 (0.00)	1.00 (0.00)
Number of concomitant medical procedures	1.00 (0.00)	5.00 (4.24)

Full analysis set (n=111).

Supplementary Table 2. Workplace productivity at each visit by Week 12

DAS28(ESR) responder status

How many days in the last month did the patient miss work because of arthritis?				
	Week 12 Responders		Week 12 Non-Responders	
	n	Mean (SD)	n	Mean (SD)
<i>Baseline</i>	42	4.17 (9.02)	11	2.09 (4.35)
Week 12	44	1.16 (5.25)	11	3.00 (8.98)
Week 26	40	2.73 (7.94)	11	5.64 (12.06)
Week 52	33	1.09 (5.41)	10	6.40 (12.50)
Week 78	27	1.22 (3.88)	6	0.00 (0.00)
How many days in the last month was the patient's productivity at work reduced by half or more due to arthritis?				
	Week 12 Responders		Week 12 Non-Responders	
	n	Mean (SD)	n	Mean (SD)
<i>Baseline</i>	42	5.62 (8.29)	11	7.82 (10.04)
Week 12	44	2.84 (7.39)	11	3.36 (8.97)
Week 26	40	2.18 (5.34)	11	5.00 (10.19)
Week 52	33	1.48 (3.81)	10	3.60 (9.37)
Week 78	27	1.00 (4.44)	6	2.50 (6.12)
In the last month, how much has arthritis interfered with the patient's work productivity? [a]				
	Week 12 Responders		Week 12 Non-Responders	
	n	Mean (SD)	n	Mean (SD)
<i>Baseline</i>	42	5.02 (3.11)	11	4.09 (2.98)
Week 12	44	2.18 (2.94)	11	3.18 (3.06)
Week 26	40	2.95 (3.58)	11	4.55 (3.62)
Week 52	33	1.30 (2.16)	10	3.20 (3.91)
Week 78	27	1.56 (2.36)	6	1.33 (3.27)

Full analysis set. Answered by employed patients only. [a] 0–10 scale, where 0=no interference and 10=complete interference.

Supplementary Table 3. Household productivity at each visit by Week 12

DAS28(ESR) responder status

How many days in the last month did the patient not do household work because of arthritis?				
	Week 12 Responders		Week 12 Non-Responders	
	n	Mean (SD)	n	Mean (SD)
<i>Baseline</i>	79	9.75 (9.78)	27	10.15 (10.78)
Week 12	79	5.04 (8.03)	28	7.82 (10.41)
Week 26	72	5.51 (8.27)	25	7.96 (11.69)
Week 52	63	5.19 (8.39)	19	2.37 (4.31)
Week 78	50	6.08 (10.27)	17	6.47 (9.96)
How many days in the last month was productivity in the household reduced by half or more due to arthritis?				
	Week 12 Responders		Week 12 Non-Responders	
	n	Mean (SD)	n	Mean (SD)
<i>Baseline</i>	79	8.30 (9.27)	27	8.26 (9.58)
Week 12	76	5.30 (7.93)	28	7.04 (10.14)
Week 26	72	4.21 (5.93)	25	6.88 (10.31)
Week 52	62	3.66 (6.09)	19	7.05 (9.72)
Week 78	50	3.70 (7.96)	17	6.59 (8.95)
How many days in the last month did the patient miss family, social or leisure activities because of arthritis?				
	Week 12 Responders		Week 12 Non-Responders	
	n	Mean (SD)	n	Mean (SD)
<i>Baseline</i>	79	3.52 (6.22)	27	3.52 (7.71)
Week 12	78	1.42 (4.88)	28	1.29 (2.62)
Week 26	72	1.49 (4.06)	25	2.08 (6.06)
Week 52	63	1.43 (5.00)	19	1.74 (4.68)
Week 78	50	1.84 (6.10)	17	4.53 (10.00)
How many days in the last month did the patient have to hire outside help because of arthritis?				
	Week 12 Responders		Week 12 Non-Responders	
	n	Mean (SD)	n	Mean (SD)
<i>Baseline</i>	79	0.76 (2.47)	27	1.07 (3.89)
Week 12	78	1.10 (4.71)	28	1.64 (5.91)
Week 26	72	0.75 (3.64)	25	0.84 (2.38)
Week 52	63	0.81 (4.05)	19	0.95 (3.29)

RA-PROACTIVE Supplementary Data

Week 78	50	1.76 (6.08)	17	0.82 (2.56)
In the last month, how much has arthritis interference with the patient's household work productivity? [a]				
	Week 12 Responders		Week 12 Non-Responders	
	n	Mean (SD)	n	Mean (SD)
<i>Baseline</i>	<i>79</i>	<i>6.13 (3.30)</i>	<i>27</i>	<i>5.89 (2.81)</i>
Week 12	77	3.39 (3.16)	28	4.64 (3.70)
Week 26	72	3.53 (3.67)	25	4.16 (3.52)
Week 52	63	3.00 (3.20)	19	3.32 (3.04)
Week 78	50	3.14 (3.56)	17	3.59 (3.55)

Full analysis set. [a] 0–10 scale, where 0=no interference and 10=complete interference.

Supplementary Table 4. PASS response at each visit by Week 12 DAS28(ESR) responder status

n (%)	Week 12 Responders (n=80)	Week 12 Non-Responders (n=31)
<i>Baseline</i>	7 (8.8)	3 (9.7)
Week 12	56 (70.0)	6 (19.4)
Week 26	50 (62.5)	10 (32.3)
Week 52	48 (60.0)	14 (45.2)
Week 78	36 (45.0)	10 (32.3)

Full analysis set (n=111). Patients were asked to rate their current symptom state by answering the following question with a 'Yes/No' response: "Considering the full range of activities you engage in as part of your normal everyday life, your level of pain, and your level of disability, if you were to remain in your present condition for the next few months, would you consider your current health state satisfactory?". [The numbers above correspond to the proportion of patients who responded 'Yes'.](#)

DAS28(ESR): 28-joint count disease activity score, calculated with erythrocyte sedimentation rate;

PASS: Patient acceptable symptom state.

Supplementary Table 5. EQ-5D-3L responses at baseline and Week 78

Summary of EQ-5D-3L health status (visual analogue scale) [a]			
Mean (SD)	Week 12 Responders (n=80)		Week 12 Non-Responders (n=31)
Baseline	49.7 (22.05)		48.4 (14.41)
Week 78	62.9 (26.74)		54.2 (25.19)
Mobility			
n (%) [b]	Response	Week 12 Responders	Week 12 Non-Responders
Baseline	n	80	31
	No problems	14 (17.5)	4 (12.9)
	Some problems	66 (82.5)	27 (87.1)
	Unable to do	0	0
Week 78	n	63	23
	No problems	28 (44.4)	9 (39.1)
	Some problems	35 (55.6)	14 (60.9)
	Unable to do	0	0
Self-care			
n (%) [b]	Response	Week 12 Responders	Week 12 Non-Responders
Baseline	n	80	31
	No problems	26 (32.5)	7 (22.6)
	Some problems	51 (63.8)	23 (74.2)
	Unable to do	3 (3.8)	1 (3.2)
Week 78	n	64	23
	No problems	38 (59.4)	10 (43.5)
	Some problems	24 (37.5)	12 (52.2)
	Unable to do	2 (3.1)	1 (4.3)
Usual activities			
n (%) [b]	Response	Week 12 Responders	Week 12 Non-Responders
Baseline	n	80	31
	No problems	8 (10.0)	1 (3.2)
	Some problems	64 (80.0)	25 (80.6)
	Unable to do	8 (10.0)	5 (16.1)
Week 78	n	64	23
	No problems	24 (37.5)	9 (39.1)


RA-PROACTIVE Supplementary Data

	Some problems	35 (54.7)	12 (52.2)
	Unable to do	5 (7.8)	2 (8.7)
Pain/Discomfort			
n (%) [b]	Response	Week 12 Responders	Week 12 Non-Responders
Baseline	n	80	31
	No problems	0	1 (3.2)
	Some problems	66 (82.5)	24 (77.4)
	Unable to do	14 (17.5)	6 (19.4)
Week 78	n	64	22
	No problems	15 (23.4)	4 (18.2)
	Some problems	42 (65.6)	14 (63.6)
	Unable to do	7 (10.9)	4 (18.2)
Anxiety/Depression			
n (%) [b]	Response	Week 12 Responders	Week 12 Non-Responders
Baseline	n	80	30
	No problems	37 (46.3)	12 (40.0)
	Some problems	40 (50.0)	16 (53.3)
	Unable to do	3 (3.8)	2 (6.7)
Week 78	n	64	23
	No problems	47 (73.4)	18 (78.3)
	Some problems	13 (20.3)	4 (17.4)
	Unable to do	4 (6.3)	1 (4.3)

Full analysis set. [a] LOCF imputation; 100 mm scale, where 0=worst imaginable health state and 100=best imaginable health state. [b] Percentages for the total headcount by dimension. EQ-5D-3L: Euro Quality of Life with 5 dimensions and 3 levels questionnaire; LOCF: Last observation carried forward.

Supplementary Figure 1. DAS28(ESR) response at Week 78 by Week 12

DAS28(ESR) responder status – RF and ACPA subgroup analyses



NRI imputation. ACPA: Anti-citrullinated peptide antibodies; DAS28(ESR): 28-joint count disease activity score, calculated with erythrocyte sedimentation rate; NRI: Non-responder imputation; RF: Rheumatoid factor.